Published in Oncogene on January 01, 1989
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A (2000) 2.19
The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res (2004) 2.04
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat (2008) 1.62
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol (2005) 1.33
c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer (1991) 1.30
Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg (1995) 1.24
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res (2000) 1.23
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer (1990) 1.04
c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol (1992) 0.98
c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol (1991) 0.96
Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. Br J Cancer (1995) 0.90
A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol (2011) 0.87
Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Breast Cancer Res (2008) 0.83
Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol (1992) 0.83
c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer (1992) 0.80
Autocrine growth factors and solid tumor malignancy. West J Med (1991) 0.80
Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer (1990) 0.80
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines. BMC Cancer (2006) 0.78
When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Cells (2014) 0.78
HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer. J Cancer Res Clin Oncol (2008) 0.78
A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcome. Ecancermedicalscience (2010) 0.75
Association between hormone receptors and HER-2/neu is age-related. Int J Clin Exp Pathol (2015) 0.75
Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). J Cancer Res Clin Oncol (2005) 0.75
The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell (1995) 9.98
Mex67p, a novel factor for nuclear mRNA export, binds to both poly(A)+ RNA and nuclear pores. EMBO J (1997) 5.61
Repeat sudden unexpected and unexplained infant deaths: natural or unnatural? Lancet (2005) 5.00
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 4.20
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer (2006) 3.78
Sudden unexplained infant death in 20 regions in Europe: case control study. Lancet (2004) 3.60
New equities of information in an electronic age. BMJ (1995) 3.20
Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia (2006) 2.88
[Unobserved death of an infant: cot death?]. Ned Tijdschr Geneeskd (1999) 2.66
Dividing work, sharing work, and in-between: marriage patterns and depression. Am Sociol Rev (1983) 2.22
Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res (1990) 2.09
CRM1-mediated recycling of snurportin 1 to the cytoplasm. J Cell Biol (1999) 2.08
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res (2000) 2.03
Mode of delivery is associated with maternal and fetal endocrine stress response. BJOG (2006) 1.81
Quantitative detection of reverse transcriptase-PCR products by means of a novel and sensitive DNA stain. PCR Methods Appl (1995) 1.74
Circulating breast cancer cells are frequently apoptotic. Am J Pathol (2001) 1.72
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia (2006) 1.70
Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. J Biol Chem (2001) 1.67
Dummy use, thumb sucking, mouth breathing and cot death. Eur J Pediatr (1999) 1.66
Quantitative immunohistochemistry of factor VIII-related antigen in breast carcinoma: a comparison of computer-assisted image analysis with established counting methods. Am J Clin Pathol (1996) 1.60
The effect of a second-generation 3D endoscope on the laparoscopic precision of novices and experienced surgeons. Surg Endosc (1999) 1.58
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer (2013) 1.57
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res (2001) 1.57
p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer (1997) 1.54
Sudden unexpected death in infancy: epidemiologically determined risk factors related to pathological classification. Acta Paediatr (1998) 1.53
Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. Breast Cancer Res Treat (2010) 1.52
Fatal rotavirus gastroenteritis: an analysis of 21 cases. Am J Dis Child (1978) 1.49
Rapid emergence of baculovirus resistance in codling moth due to dominant, sex-linked inheritance. Science (2007) 1.42
[Placebo-controlled study of melbrosia in treatment of climacteric symptoms]. Wien Med Wochenschr (1994) 1.42
Paraneoplastic encephalomyelitis antigens bind to the AU-rich elements of mRNA. Neurology (1995) 1.41
Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on. Lancet (1990) 1.41
HLA-B*27 typing by group-specific hybridization in microtiter plates. Tissue Antigens (1998) 1.41
[Tumoral vascular density in breast tumors and their effect on recurrence-free survival]. Chirurg (1994) 1.40
MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathologic parameters. J Soc Gynecol Investig (2003) 1.40
Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol (2004) 1.40
[Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause]. Dtsch Med Wochenschr (1992) 1.39
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie (2003) 1.38
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol (2012) 1.37
Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol (1999) 1.34
Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol (2001) 1.33
The surgical treatment of bony metastases of the spine and limbs. J Bone Joint Surg Br (2002) 1.33
Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol (1997) 1.30
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Hardship and depression. J Health Soc Behav (1985) 1.28
High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost (2009) 1.28
Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer (1994) 1.27
Oct-4 expression in human endometrium. Mol Hum Reprod (2006) 1.26
Case-control study of current validity of previously described risk factors for SIDS in The Netherlands. Arch Dis Child (1998) 1.26
EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res (1997) 1.26
Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat (2001) 1.25
Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet (1999) 1.24
An unusual chemical reactivity of Sm site adenosines strongly correlates with proper assembly of core U snRNP particles. J Mol Biol (1999) 1.24
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia (2006) 1.22
Idiopathic infantile arterial calcification in siblings: radiologic diagnosis and successful treatment. J Pediatr (1978) 1.22
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer (2007) 1.20
The thymus in acquired immune deficiency syndrome. Comparison with other types of immunodeficiency diseases, and presence of components of human immunodeficiency virus type 1. Am J Pathol (1989) 1.20
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer (2003) 1.19
Dendritic cell-based vaccination in solid cancer. J Clin Oncol (2003) 1.18
Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia (2004) 1.18
Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res (1984) 1.17
Risk and preventive factors for cot death in The Netherlands, a low-incidence country. Eur J Pediatr (1998) 1.17
Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer (1997) 1.16
Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat (1999) 1.15
Congenital aplasia of parathyroid glands and thymus. Arch Dis Child (1967) 1.14
Antibodies to the mycobacterial 65-kd heat-shock protein are reactive with synovial tissue of adjuvant arthritic rats and patients with rheumatoid arthritis and osteoarthritis. Am J Pathol (1990) 1.14
5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res (1997) 1.13
Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod (2001) 1.13
High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol (2009) 1.13
Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology (1998) 1.12
Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat (2003) 1.12
The use of a breast symmetry index for objective evaluation of breast cosmesis. Breast (2007) 1.12
Structural study of long arm fragments of laminin. Evidence for repetitive C-terminal sequences in the A-chain, not present in the B-chains. Eur J Biochem (1988) 1.11
Long-term results after laparoscopic unroofing of solitary symptomatic congenital liver cysts. Surg Endosc (2000) 1.11
Clinical evaluation of the WOMAC 3.0 OA Index in numeric rating scale format using a computerized touch screen version. Osteoarthritis Cartilage (2002) 1.10
Organization of neuronal systems mediating presynaptic inhibition of group II muscle afferents in the cat. J Physiol (1995) 1.10
Fever, cancer incidence and spontaneous remissions. Neuroimmunomodulation (2001) 1.08
Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost (1997) 1.08
Presence of nanobacteria in psammoma bodies of ovarian cancer: evidence for pathogenetic role in intratumoral biomineralization. Histopathology (2004) 1.07
[Urology needs health services research: the case of small renal tumours]. Urologe A (2011) 1.07
Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer. Br J Cancer (1995) 1.06
Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol (1994) 1.06
Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol (1995) 1.05
Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost (2011) 1.05
Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol (2006) 1.05